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Abstract
 .The antiatherogenic properties of repeated injections of egg phosphatidylcholine large unilamellar vesicles LUVs of
100 nm diameter were tested in an experimental model for atherosclerosis. Forty eight rabbits were divided into two diet
 .groups fed standard rabbit chow or fed a cholesterol-enriched diet 0.5% by weight to induce the formation of
atherosclerotic lesions. Prior to the initiation of LUV therapy, the cholesterol diet was ceased and all animals were returned
to standard rabbit chow. The treatment protocol consisted of a total of 10 bolus injections of vesicles, at a phospholipid dose
of 300 mgrkg body weight or the equivalent volume of saline, with one injection given to each animal every 10 days. LUV
injections brought about a large movement of cholesterol into the blood pool and resulted in a significant reduction in the
cholesterol content as well as the degree of surface plaque involvement of aortic tissue in atherosclerotic animals. Most
notably, the thoracic aorta of LUV-treated animals exhibited a 48% reduction in tissue cholesterol content per gram of
protein compared to saline-treated controls. Histochemical analyses revealed that aortas from animals receiving the repeated
injections of LUVs displayed less cholesterol deposits in lesions, and a moderate reduction in intimal-to-medial thickness.
This regression of atheroma, induced by LUV therapy, was observed even though animals possessed persistent elevated
plasma cholesterol levels after the cholesterol-enriched diet was ceased. These results suggest that repeated injections of
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LUVs, working with endogenous HDL, may be a useful therapy in the management of atherosclerosis. q 1998 Elsevier
Science B.V.
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1. Introduction
Coronary heart disease, of which most cases are
linked to atherosclerosis, remains one of the leading
causes of death in the western world. Current preven-
tive management of the disease focuses on the use of
drugs along with dietary restrictions to induce
favourable changes in plasma cholesterol levels. For
 .example, when plasma low density lipoprotein LDL
w xconcentrations are kept to near normal levels 1 or
w xantioxidant therapies 2 which suppress the forma-
tion and the uptake of modified LDL particles are
used, there is evidence that the progression and accu-
mulation of lipids in lesions can be halted. However,
while these drugs which lower plasma cholesterol
levels induce favourable changes that appear to slow
w xthe progression 3 , or even promote the regression of
w xatherosclerosis 4,5 , the responses to treatment are
varied. This is presumably because the primary effect
of such therapies is to reduce serum cholesterol and
not to directly cause the mobilization of cholesterol
which forms the bulk of plaque that can occlude
arteries. There is, however, increasing evidence that
processes which stimulate the mobilization of periph-
eral cell cholesterol and promote its transport to the
liver for catabolism may be important events in the
w xprevention of atherosclerosis 6,7 . High density
 .lipoprotein HDL is believed to be the physiological
acceptor of tissue cholesterol and high levels of HDL
cholesterol is inversely correlated with the develop-
ment of heart disease. Consequently, this has led to
searches for ways to raise HDL levels by drug inter-
w xvention 6 or to stimulate the reverse transport of
cholesterol by alternative means through the infusion
w x w xof artificial HDL particles 7,8 or liposomes 9,10 .
Many years ago, the repeated intravenous adminis-
tration of phospholipid was shown to reverse experi-
mentally induced atherosclerosis in a variety of ani-
 w x .mal models see 9 for review . When hydrated in
aqueous buffer these phospholipids self-assemble into
spherical bilayers known as liposomes or vesicles.
When these particles are administered intravenously
at sufficient doses, they remain as distinct particles in
the bloodstream and are capable of extracting choles-
w xterol from lipoproteins and peripheral tissue 9,10 .
Thus, circulating liposomes act as thermodynamic
‘sinks’ for sterol, reducing the chemical potential of
plasma cholesterol, and as a result, sterol from pe-
ripheral tissues, including those present in the arterial
w xwall are mobilized 9 . Liposomes because of their
large size are confined mainly within the vasculature.
In order to mobilize peripheral cholesterol stores,
liposomes would likely have to interact endogenous
w xsmall cholesterol acceptors in plasma 9,11 , particu-
larly HDL, which can readily access interstitium and
w xcell surfaces. It had been proposed 9 and recently
w xdemonstrated in vitro 11 that two specific particle
interactions, namely remodeling and shuttling, occur
between HDL and phospholipid vesicles to promote
w xthe mobilization of cellular cholesterol 11 . During
remodeling, the composition of HDL and liposomes
are altered resulting in cholesterol-depleted phospho-
lipid-enriched HDL that exhibited an increased ca-
pacity to mobilize cellular cholesterol. During shut-
tling, HDL acts to transport cholesterol back and
forth from cells to liposomes. Presumably, as a result
of these interactions in vivo, HDL that has been
remodeled can scavenge more sterol from vascular
w xand extravascular tissues 9–13 . Since intravenously
administered liposomes are cleared mainly by the
liver, liposomes are thought to enhance the capacity
of HDL to promote the reverse transport of choles-
w xterol 9,10,14 .
Despite these seemingly striking results, the devel-
opment of phospholipid therapy for use to rapidly
regress of atherosclerotic plaques in humans, has
largely been ignored. The reasons for this are not
entirely clear, but might be attributed to the use of
ill-defined lipid preparations whose cholesterol mobi-
lizing properties were not well characterized. In addi-
tion, the intravenous administration of these early
preparations were tedious and involved large doses of
w xphospholipid infused over a period of 8 h 15 or
intensive, often bi-weekly, bolus injections of smaller
w xphospholipid doses 16,17 . Moreover, although the
mechanisms by which circulating liposomes mediate
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the massive removal of cholesterol deposits from
peripheral cells were proposed over a decade ago,
w xonly recently have they been demonstrated 11 . Fi-
nally, recent evidence suggests that not all agents
which promote the mobilization of cholesterol to the
liver in vivo may be beneficial. For example, the
delivery of cholesterol by an apoE-rich HDL fraction
w xin rats 18 resulted in no change in biliary output of
cholesterol or bile acids, but stimulated hepatic acyl-
CoA:cholesterol transferase and caused increased
VLDL secretion. In addition, the repeated intra-
venous injections of small unilamellar vesicles
 .SUVs in rabbits suppresses LDL receptor and
w xHMG-CoA reductase mRNA expression 14 , and
provokes a subsequent increase in apoB-rich athero-
w xgenic lipoproteins 13,14,19 . Also, the intravenous
infusion of apolipoprotein A-I phospholipid disks in
w xhumans 8 causes a subsequent rise in plasma LDL
levels. These potentially harmful side effects are
more consistent with events leading to the promotion,
not the prevention of atherosclerosis.
We have taken steps to overcome these hurdles by
developing and testing a vesicle formulation suitable
for clinical use. In a recent report, a variety of
liposomal preparations were characterized to deter-
mine which was the most effective at mobilizing
w xcholesterol in vivo 10 . These studies were con-
ducted in mice and demonstrated that liquid crys-
 .talline, large unilamellar vesicles LUVs with a mean
diameter of approximately 100 nm were capable of
removing 0.5 mol of cholesterol to the liver for every
mole of phospholipid injected. These vesicles are
easily prepared in large quantities using pharmaceuti-
cally accepted procedures and are apparently non-
w xtoxic even at high doses 20 . LUVs composed of egg
 .phosphatidylcholine EPC represent an ideal size
and composition that maximizes the surface area
capable of accepting cholesterol in vivo, and are
capable of circulating with half-times much longer
than multilamellar or small unilamellar preparations
w x10 . Most importantly, however, LUVs may repre-
sent a unique vesicle preparation because they appear
to direct a net transport of peripheral tissue choles-
terol to a distinct metabolic pool in the liver that does
not provoke a subsequent rise in plasma LDL concen-
w xtrations 14 . Thus, it was predicted on the basis of
these criteria, that bolus injections of LUVs, given at
reasonable phospholipid doses and using a manage-
able treatment regimen, would promote a significant
regression of atheroma. Consequently, the ability of
these optimized vesicles to remove cholesterol and
cholesteryl ester deposits from atherosclerotic lesions
in cholesterol-fed rabbits were tested.
2. Methods
2.1. Materials
 .EPC )97% purity was purchased from Prince-
 .ton Lipids Princeton, NJ . The cholesterol supple-
 .mented diet 0.5% by weight was obtained from
 .Teklad Premier Madison, WI . Blood collection tubes
 .and butterfly needles 23 gauge were from Becton–
 .Dickinson Missisauga, Ontario . Ketamine, xylazine,
heparin, Innovar and Euthanyl were supplied by MTC
Pharmaceuticals, Janssen Pharmaceutica and Organon
 .Technika Ontario . Bio-Gel A-15m was purchased
from Bio-Rad. Prepacked Solid Phase silica gel
columns were acquired from Burdick and Jackson
 .Muskegon, MI . All chemical and solvents were of
analytical grade purchased from BDH Chemicals
 .Vancouver, BC .
2.2. Rabbits
 .Forty eight New Zealand White NZW rabbits
were housed in wire cages at the Animal Unit of the
 .Research Centre Shaughnessy Site conforming to
guidelines set by the Canadian Council on Animal
Care and the University of British Columbia. The
animals were maintained in a controlled temperature
environment with a 12 h darkrlight cycle. Approxi-
mately 150 g of food were given per animal per diem
while access to water was unlimited.
2.3. Experimental design
The correlation between hypercholesterolemia and
the onset and progression of atherosclerosis in the
w xrabbit is well established 21 . It is known that the
response of rabbits to dietary cholesterol is varied
with some animals behaving as hyper-responders
 .large increase in plasma cholesterol and others clas-
sified as hypo-responders. Consequently, the rabbits
used in this study were carefully screened so that an
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equal distribution of hypo- and hyper-responders were
included in each experimental group. The 48 NZW
weanlings were screened by measuring their response
 .to the cholesterol-enriched diet Teklad diet 0533 .
Briefly, blood was drawn from animals to determine
baseline plasma cholesterol concentrations then all
animals were fed the 0.5% cholesterol-enriched diet
for one week. Plasma cholesterol levels were moni-
tored on a weekly basis until these returned to base-
line. Animals were matched by the extent of the rise
in their plasma cholesterol levels as well as the rate at
which the levels returned to normal. Hyper- and
hypo-responders were spread between two groups of
24 and were subsequently fed either standard rabbit
chow or the cholesterol-enriched diet for 20 weeks to
induce atherosclerotic plaque formation see experi-
.mental outline in Fig. 1 . During this time, plasma
lipid levels were monitored on a monthly basis to
facilitate the randomisation of animals into the re-
spective treatment groups. Two animals were eutha-
nized due to complications probably associated with
stress resulting from handling and were not used in
the final analyses. After the diet induction period,
five animals per group were randomly selected by an
outside observer, and sacrificed, to establish the for-
mation of lesions, and serve as the standard or base-
line against which the effectiveness of LUV treat-
ment was assessed. Thereafter, all remaining animals
were fed regular rabbit chow until the conclusion of
the study.
The 18 remaining animals in each diet group were
subsequently divided into two subgroups of nine see
.Fig. 1 and were paired on the basis of their response
to the diet phase of the protocol. The four treatment
 .groups were: 1 Saline-treated cholesterol-fed ani-
 .  .mals, 2 LUV-treated cholesterol-fed animals, 3
 .saline-treated standard diet animals and 4 LUV-
treated standard diet animals. Thereafter, 9 of the
animals in each diet group were treated with bolus
injections of LUVs given at a dose of 300 mg phos-
pholipidrkg body weight or the equivalent volume of
saline. Treatment was initiated 4 weeks after their
return to standard rabbit chow and was given over a
100 day period. Treatment consisted of a total of 10
injections of LUVs 300 mgrkg body weight, ;
.10 ml volume or saline, with one injection adminis-
tered into the marginal ear vein every 10 days.
Fig. 1. Experimental design used to test the efficacy of liposomal
therapy. Forty eight NZW rabbits were paired on the basis of
their response to a 0.5% cholesterol-enriched diet and subse-
quently divided into two groups of 24 fed either the cholesterol-
enriched diet or standard rabbit chow. After 20 weeks of feeding,
5 animals per group were sacrificed to establish baseline charac-
teristics of atherosclerotic lesions. The 18 animals in each diet
group were further divided into two subgroups of nine. Animals
maintained on standard rabbit during the diet induction period
were matched on the basis of the previous screening method
described in the methods. The 18 animals fed the cholesterol-en-
riched diet for 20 weeks were paired on the basis of their
response to the initial screening as well as the extent by which
plasma cholesterol levels were elevated during the diet phase of
the protocol. Treatment was initiated after all animals had been
returned to standard chow for 4 weeks and consisted of a bolus
 .injection of LUVs 300mg phospholipidrkg body weight or the
equivalent volume of saline with one injection given every 10
days for a total of 10 injections.
2.4. Vesicle preparation
The rabbits ranged from 4–6 kg in weight and thus
each treatment for the 18 rabbits receiving LUVs
required the preparation of approximately 150 ml of
LUVs that were prepared at a concentration of
200 mgrml. Typically, 6 g aliquots of EPC were
placed into sterile 50 ml polypropylene conical tubes,
hydrated with 30 ml of sterile-filtered 150 mM NaCl,
 .20 mM Hepes, pH 7.4 Hepes-buffered saline , vor-
texed and kept overnight at 48C. This procedure
 .generated multilamellar vesicles MLVs which were
subsequently used to generate LUVs by extrusion.
Ten ml portions of MLVs were forced through two
stacked polycarbonate filters of 100 nm pore size
using an 10 ml capacity Extruder Lipex Biomem-
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.branes, Vancouver, BC , under medium pressures
 .300–500 psi . Each 10 ml portion was extruded
through the device 10 times to yield LUVs of approx-
imately 100 nm diameter, as previously described
w x10 . Vesicle diameters were determined by quasi-
 . w xelectric light scattering QELS 10 . The average
diameter of the LUVs used for the 10 treatments was
114"7 nm.
2.5. Collection of blood and tissue samples
Approximately 100 ml of Innovar was given to
promote calmness and vessel dilation in animals to
ease routine bleedings necessary for plasma lipid
analyses. To anaesthesize the animals for the final
 .blood collection, ketamine 40 mgrkg and xylazine
 .8 mgrkg were given intramuscularly to sedate the
animals. Approximately 10 min later, 50 units of
 .heparin Hepalean followed by a lethal dose of
 .phenobarbitol Euthanyl were perfused into the
marginal ear vein before laparotomy. Organs were
removed, rinsed in saline and immediately frozen in
liquid nitrogen. The heart, with the entire aorta at-
tached, was collected and kept in ice cold saline. The
animals were sacrificed in groups of 8–10 on alter-
nate days. The organs and aortas were randomized
and allocated for the different analyses by an outside
observer prior to any processing. The treatment regi-
men of the aorta being processed or analysed was not
known until all measurements were completed and
the samples were decoded.
2.6. Preparation of aortas for analyses
Each aorta was separated from the heart at the
aortic valve and was very carefully cleaned to re-
move any adherent adventitial fat. The aortas were
then cut along the ventral surface, spread open, and
photographed on a black surface. The developed
photographs were later used in conjunction with the
negatives to aid in the collection of digitization data
as well as to facilitate the division of the aortas into
three regions: arch, thoracic and abdominal segments
w xas described by Rosenfeld et al. 22 . Six aortas from
the nine animals per treatment group were stored at
y208C prior to lipid analyses. The remaining three
aortas were immediately fixed in 10% neutral buffered
w xformalin for at least 48 h, stained with Sudan IV 23 ,
re-photographed, and were subsequently used for his-
tological analyses. At the time of lipid analyses,
aortas were pat dried, divided into three segments and
a wet weight and length were determined prior to
mincing the tissues in Hepes-buffered saline using a
Polytron homogenizer. Two additional washes of the
probe were carried out to ensure quantitative recov-
ery. Lipid, histochemical and image analyses on all
tissue samples were performed on randomized and
independently coded samples.
2.7. Separation of ˝esicles from lipoproteins
Plasma samples were applied to 27=1.5 cm Bio-
Gel A15m gel filtration columns equilibrated with
150 mM NaCl, 10 mM Tris, 0.1% EDTA, 0.3% NaN3
 .pH 7.4 to re-isolate LUVs from plasma lipopro-
w xteins, as previously described 10 . Briefly, plasma
collected after LUV or saline injections were applied
to columns and LUVs eluted in the void volume, and
were well separated from the remaining lipoproteins.
 .The cholesterol-to-phospholipid C:P ratios of LUVs,
the void volume fractions of saline controls, and
lipoproteins were determined following lipid extrac-
tions of pooled samples.
2.8. Digitization
Photographic negatives obtained from all unstained
 .aortas and the 12 stained aortas were illuminated on
a light box and a digitized image was generated using
 .a Microcomputer Imaging Device Imaging Systems .
The % plaque involvement was calculated by divid-
ing the area occupied by surface plaque by the area
occupied by the entire aorta. These areas were easily
distinguished by the computer due to distinct differ-
ences in the degree of shading between plaques areas
and uninvolved aortic tissue. Moreover, computer
generated values for % surface plaque involvement
from negatives of Sudan IV-stained tissues and from
the corresponding negatives of the same tissue un-
stained were identical. The assessment of the %
atherosclerotic plaque involvement of the coded sam-
ples were performed by two observers and their
results were averaged. Inter-observer variation was
within "5%.
( )W.V. Rodrigueza et al.rBiochimica et Biophysica Acta 1368 1998 306–320 311
2.9. Lipid analysis
Cholesterol and phospholipid content of the aortas
and livers were measured after Bligh and Dyer lipid
w xextraction of the homogenates 24 . The lipid content
of erythrocytes was determined after extraction using
w xthe procedure of Rose and Oklander 23 . Total
 .cholesterol, unesterified cholesterol UC , and
 .cholesteryl esters CE were determined according to
w xthe method of Rudel and Morris 25 . Cholesterol and
cholesteryl esters were separated by silica gel chro-
matography on pre-packed Solid Phase Silica Gel
 .columns 200 mg silica per column placed in 16=
100 mm test tube carriers. Cholesteryl esters were
eluted with 1 ml methylene chloride whereas choles-
terol was collected following the transfer of the
columns to a new carrier and the addition of 1 ml of
 .methylene chloridermethanol 95:5, vrv . Phospho-
lipid content was measured according to Fiske and
w xSubbarow 26 . Lipoprotein lipid profiles were deter-
mined using enzymatic procedures after precipitation
w xwith phosphotungstic acid 27 .
2.10. Protein analysis
Aliquots of aorta or liver homogenates were incu-
bated overnight at 378C with 1 ml of 1 N NaOH.
 .Thereafter, sodium dodecylsulphate SDS was added
 .to the mixture to make a 1% vrv solution necessary
to solubilize remaining particulate matter. Protein
content was quantified using the bicinchoninic acid
 .  .BCA protein assay Pierce, Rockford, IL after
incubation for 1 h at 608C and read at A against an562
albumin standard.
2.11. Histological analyses
Typically, 2–3 mm segments from the arch, tho-
racic, and abdominal aorta from each of the three
animals within each treatment group were cut, further
divided into left and right halves and embedded in
paraffin blocks. Depending on the length of the aorta,
at least 8 segments from each region were prepared
as blocks. Alternate sections of 5mm were adhered to
gelatin-coated slides from paraffin blocks and visual-
 .ized with haematoxylin and eosin H and E or
Weigart’s–van Gieson’s stains. Photographs were
taken from each paraffin block and due to the magni-
fication used, three photographs of each block were
needed to span the entire tissue on the slide. At three
standard locations on each photograph, an intimal-
to-medial ratio was determined, and from this an
average intimal-to-medial ratio was calculated for
that particular segment prepared as a block. A final
mean"standard deviation was determined for all the
sections made for a particular region and represents
the average obtained from the three animals in each
treatment group.
The morphology of plaques from animals sacri-
ficed after the diet induction period but prior to any
.treatment were also examined. Segments of aorta
were held into place with tissue mount on wooden
stages and quick frozen, first in isopentane then in
liquid nitrogen. Subsequently, alternate sections of
5 mm were adhered to polylysine-coated slides and
visualized with Sudan IV differentiated with Harris’
haematoxylin, H and E or van Gieson’s stains to
highlight lipids and collagen.
2.12. Statistical analyses
Unless otherwise indicated values are presented as
mean"standard deviation. Statistical differences be-
tween treatment groups were assessed by analysis of
variance using the two-sample t-test. Only values of
P-0.05 were considered significant.
3. Results
3.1. Establishment of lesions
The animals in this study were fed a 0.5% choles-
terol-enriched diet for 20 weeks in order to induce
intermediate lesions rather than fatty streaks. Indeed,
chemical and histological analyses of the aortas ob-
tained from animals after the diet induction period,
but prior to treatment, revealed that the plaques
formed were rich in lipid, surrounded by fibrous
tissue, and consisted of almost equivalent amounts of
UC and CE. The aortic phopholipid content was
found to be 15"4 mmolrg wet tissue and total
cholesterol was 114"28 mmolrg wet tissue, of
which there was 61"13 mmol unesterified choles-
terolrg wet tissue and 53"15mmol CErg wet tis-
sue. Animals maintained on the standard diet had
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aortic phospholipid levels of 4"0.3 mmolrg wet
tissue and total cholesterol levels, which were pre-
dominantly UC, of 10"1 mmolrg wet tissue. The
degree of surface plaque involvement in cholesterol-
fed animals was 78"14%.
3.2. Cholesterol mobilization
Animals fed the cholesterol-enriched diet exhibited
plasma total cholesterol concentrations that were 5–10
times higher than control animals fed the standard
diet. Moreover, even after the cessation of the choles-
terol-enriched diet and during the treatment period,
plasma cholesterol levels remained elevated 2–5
.times higher . This point is illustrated in a typical
time course of cholesterol mobilization resulting from
the injection of 300 mg LUV phospholipidrkg or the
equivalent volume of saline and shown in Fig. 2.
Animals previously fed the cholesterol-enriched diet
 .panel A, open circles exhibit plasma cholesterol
concentrations three times higher than control ani-
mals that were fed standard diet throughout the study
 .panel B, open squares even though the cholesterol
diet was ceased 10 weeks earlier.
The injection of LUVs resulted in a substantial
2.5-fold increase in plasma cholesterol concentrations
for both cholesterol-fed and control animals Fig. 2,
.solid symbols when compared to their corresponding
saline-treated controls. Note that the first time point
was measured at 1 h. The rise in plasma total choles-
terol concentrations observed was due solely to a rise
in UC levels. No changes in plasma CE concentra-
tions were detected following LUV injections data
. w xnot shown and are consistent with prior work 14 .
Plasma total cholesterol levels peak at 24 h before
returning to baseline levels after 5 days which corre-
lates with the removal of vesicles from the circula-
tion. The clearance profiles of LUVs are illustrated in
Fig. 3 and were determined by measuring plasma
phospholipid concentrations. Note that atherosclerotic
animals had slightly higher total phospholipid con-
centrations, nevertheless, similar clearance kinetics
were seen for both groups.
The mass of cholesterol accumulated and removed
by LUVs is a function of the rate of cholesterol
w xuptake and the rate of vesicle clearance 10 . We can
compute the rate of cholesterol uptake by LUVs
knowing the C:P ratios in vesicles at specific inter-
Fig. 2. Redistribution of cholesterol into plasma following a
treatment with LUVs. Animals were injected with EPC LUVs at
a dose of 300mg phospholipidrkg or the equal volume of saline
via the marginal ear vein. At the indicated time intervals, blood
was drawn from the medial ear artery. Plasma total cholesterol
 .  .concentrations for A saline-treated cholesterol-fed ‘ and
 .  .LUV-treated cholesterol-fed v animals; B saline-treated stan-
 .  .dard diet I and LUV-treated standard diet B animals. Each
data point represents ns4 randomly selected animals and were
measured during treatment number 4.
vals during the time course. This value was calcu-
lated from the cholesterol and phospholipid content
of vesicles re-isolated from plasma by gel filtration.
Lipid analyses revealed that the rise in plasma choles-
terol concentrations in LUV-treated animals was en-
tirely associated with the LUVs, and )90% of the
this cholesterol was UC with the remainder being CE
 .data not shown . Hence, C:P ratios of vesicles at any
given time can be calculated as follows. The numera-
tor is simply plasma cholesterol levels in LUV-treated
animals after cholesterol levels in saline-treated con-
trols are subtracted. This value is then divided by the
amount of LUV phospholipid at each time point this
is the plasma phospholipid concentration of LUV-
treated animals minus their respective saline-treated
.controls . The plasma volume of the rabbits is ap-
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Fig. 3. Phospholipid clearance during a treatment. Animals were
injected with LUVs at a dose of 300mgrkg or the equal volume
of saline via the marginal ear vein and at the indicated time
intervals blood was drawn from the medial ear artery. Total
phospholipid concentrations of plasma determined for saline-
 .  .treated cholesterol-fed ‘ , LUV-treated cholesterol-fed v ,
 .saline-treated standard diet I and LUV-treated standard diet
 .B animals. Each data point represents the same 4 animals
described in Fig. 2.
proximately 150 ml, consequently, the amount of
phospholipid removed from the circulation at each
time point can be estimated. Therefore, by multiply-
ing C:P ratios by the amount of phospholipid re-
moved at a given time interval, an estimate of choles-
terol mobilized can be made and is shown in Fig. 4.
The data is expressed as the cumulative mmoles of
Fig. 4. The cummulative amount of cholesterol removed to the
RES resulting from the injection of LUVs. The data presented
represents the mean"standard deviation of estimates made from
treatments 1, 4, and 10 with a total ns12 animals i.e. ns4
.randomly selected animals for each treatment . The estimates
shown at each time point were calculated as described in the
Section 3.
cholesterol removed as a function of time in LUV-
treated cholesterol-fed animals. Plasma cholesterol
and phospholipid concentration obtained from serial
bleeds taken during treatments number 1, 4 and 10
were used to estimate this value. The data represents
the mean"standard deviation. The analysis was not
continued beyond the point where less than 10% of
the initial phospholipid dose remains in the circula-
tion, because below this level the measurement error
was too large to determine accurate C:P ratios. After
 .104 h, approximately 1 mmol of cholesterol 387 mg
which represents approximately 50 mol% of the in-
jected phospholipid dose, is removed from the circu-
lation, and mobilized to the liver. Plasma cholesterol
concentrations measured in LUV-treated animals 24 h
post-injection showed similar increases data not
.shown suggesting that each of the LUV injections
caused equally dramatic cholesterol mobilization. Us-
ing these estimates, the complete therapeutic regimen
probably caused about 4 g of endogenous cholesterol
to be mobilized from peripheral tissue pools.
3.3. Effects of repeated injections
The goal of this research is to obtain useful pre-
clinical data that can support the development of
repeated injections of LUVs as a means to manage
atherosclerotic disease. Therefore, it was important to
ascertain whether the phagocytic cells of the reticulo-
 .endothelial system RES were compromised in their
capacity to remove LUVs from the circulation after
multiple injections of phospholipid.
It is estimated at the dose of 300 mg phospho-
lipidrkg, a transient 10-fold rise in plasma phospho-
lipid concentrations was induced, and on the average,
at the end of the 10 injections, each animal received a
 .total of 10–15 g 12–20 mmol of phospholipid. Al-
though, there is evidence that large and repeated
w xdoses of phospholipid are non-toxic in mice 10,20 ,
we are unaware of studies which have monitored the
effects of repeated phospholipid infusions on normal
clearance function in rabbits. The clearance profiles
of several injections of LUVs in cholesterol-fed rab-
 .bits are shown in Fig. 5 A . No significant differ-
ences in the rates of vesicle clearance between the
first, fourth, seventh and tenth injections were de-
 .tected. The data in Fig. 5 B also supports this obser-
vation. It shows that the concentrations of phospho-
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Fig. 5. Consequences of repeated injections of LUVs on clear-
 .ance kinetics. A Clearance profiles of LUVs measured by
plasma phospholipid concentrations over time. Data obtained
 .  .from samples taken during treatment 1 v , treatment 4 B ,
 .  .  .treatment 7 ’ , and treatment 10 % are shown. B Phospho-
lipid concentrations remaining in the circulation 24 h-post injec-
 .tions in cholesterol-fed animals v and standard diet-fed ani-
 .mals ‘ . In Panels A and B, each data point represents ns4
animals with four animals randomly selected each time.
lipid in the plasma 24 h post-injection, in both normal
and cholesterol-fed animals were similar over the
course of 10 injections. Furthermore, 5 days post-in-
jection, plasma phospholipid and cholesterol concen-
trations always returned to baseline levels suggesting
that LUV phospholipid is completely removed from
the circulation. These observations suggests that nor-
mal clearance mechanisms do not appear to be com-
promised.
At the conclusion of the study, saline-treated
cholesterol-fed animals still maintained elevated
plasma cholesterol levels whereas vesicle-treated ani-
mals had levels comparable to animals maintained on
 .the standard diet data not shown . The decrease seen
in plasma cholesterol concentrations in vesicle-treated
cholesterol-fed animals was a result of a reduction in
both plasma LDL and HDL cholesterol concentra-
tions, although the relative proportions of HDL-to-
LDL cholesterol were not affected. Also, at the end
of the study, LUV-treated and saline-treated control
animals maintained standard rabbit chow showed no
differences between their lipid profiles UC, CE,
.phospholipid or triglycerides, data not shown .
3.4. Source of liposomally accumulated cholesterol
Total erythrocyte cholesterol remained constant at
approximately 150 nmolr109 cells throughout the in-
jections and were similar to our previous results
w xobtained in mice 10 . In contrast, the C:P ratio of
lipoproteins at 1 h sampling was markedly reduced
then gradually returned to normal levels after more
 .than 48 h see Fig. 6 . This latter rise mirrors the time
course of cholesterol accumulation by vesicles re-
  ..maining in the circulation see Fig. 2 A . These
results are consistent with our earlier observations
w xwith mice 10 , and suggest that the lipoprotein pool
of cholesterol in rabbits also rapidly equilibrates with
vesicles.
Fig. 6. Cholesterol-to-phospholipid ratios measured in lipopro-
teins during LUV injection. The plasma lipoproteins were sepa-
rated from LUVs by gel filtration and pooled. Their lipid content
was measured following Bligh and Dyer extraction. C:P ratios in
 .  .four saline controls B and four LUV-treated animals v
during treatment number 4 are shown. Values were statistically
significant over the first 8 h.
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3.5. Assessment of atherosclerotic plaque in˝ol˝e-
ment
The extent of progression or regression of athero-
sclerotic lesions was assessed by three complemen-
 .tary methods: 1 chemical analysis of lipid and
 .protein content which reflects lesion bulk; 2 assess-
ment of the extent of plaque formation on the surface
 .of aortas by image analysis; and 3 histochemistry to
examine the morphology and intimal thickening of
the lesions.
3.6. Aortic lipid content and digitization
Results presented in Fig. 7 summarize the extent
of lipid infiltration and surface involvement in the
 .whole aorta WH , and the three segments, which
 .  .were designated as the arch AR , thoracic TH , and
 .abdominal AB regions. The lipid content is ex-
pressed per gram of protein. It was found that on
average, the protein content of aortas from treated
and untreated animals were not statistically different
with values for saline-treated and LUV-treated ani-
mals being 0.08"0.04 g proteinrg wet tissue and
0.08"0.03 g proteinrg wet tissue, respectively. The
data is expressed as lipid content per gram of protein
weight rather than per gram of wet weight to mini-
mize differences in the extent of tissue hydration.
Although not shown, the same degree of statistical
differences were observed between treatment groups
when aortic lipid levels were compared on the basis
 .of wet weight. Fig. 7 A shows that LUV-treated
cholesterol-fed animals exhibit a 30% reduction in
the UC content of the whole aorta. The bulk of this
loss, however, occurred in the thoracic region which
exhibits a substantial 50% reduction of UC compared
to their saline-treated controls. The lipid content for
the abdominal segment were very variable and al-
though mean values for LUV-treated animals were
60% lower than those of saline-treated controls, these
 .differences were not statistically different P-0.1 .
A power analysis would suggest that increasing the
 .number of animals though not feasible in this study
might reveal a true difference. The arch region was
least affected by LUV treatment, but nevertheless,
cholesterol content of LUV-treated animals were re-
duced by approximately 10% at a significance level
P-0.05. Similar trends were seen for CE content
Fig. 7. Assessment of aortic lipid content and the degree of
 .  .plaque involvement. A Cholesterol content UC of the whole
 .  .  .  .WH , arch AR , thoracic TH and abdominal AB aorta
 .expressed per g of protein weight. B Cholesteryl ester content.
 .C Extent of plaque involvement quantitated by digitization. The
percent plaque involvement was determined from the area of
surface plaque observed and the total area of the aorta being
 .analysed. 1 Solid bars represent saline-treated cholesterol-fed
 .animals; 2 hatched bars represent LUV-treated cholesterol-fed
 .animals; 3 empty bars represent saline-treated standard diet
 .animals; and 4 dotted bars represent LUV-treated standard diet
 .animals. Values shown are the mean"SEM. P -0.05 ) . Note
that six animals were used for lipid analyses and data from nine
unstained tissues were used for digitization.
  ..   ..Fig. 7 B and for surface involvement Fig. 7 C .
In all cases, the most significant and extensive reduc-
tions in lipid content were found in the thoracic
region of LUV-treated animals. It is important to note
that the cholesterol content of the lesions, after treat-
ment with saline for 3 months, did not differ from
levels measured in animals sacrificed prior to any
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treatment. Prior to therapy, but after cessation of the
cholesterol enriched diet, these aortas were found to
have 61"13 mmol UCrg wet weight tissue whereas
even after saline-treatment and a return to normal diet
for more than 12 weeks, aortic cholesterol levels
were essentially unchanged and were found to be
58"6 mmol UCrg wet tissue. In contrast, LUV-
treated animals showed lower levels of 45"4 mmol
UCrg wet tissue. These data were not compared per
g protein weight because the protein content of aortic
tissue increased during the treatment phase of the
diet. Nevertheless, these results suggest that there
appears to be no progression or regression of disease
during the treatment period in the absence of LUV
therapy.
3.7. Histochemical analyses of aortic samples
Digitized photographic negatives were used to
quantitate the extent of plaque involvement while
histochemical analyses were used to determine the
depth and nature of lesions. Extensive raised plaques
 .intimal thickening were observed in the cholesterol-
fed animals as expected from an inspection of gross
surface morphology. Generally, plaques in choles-
terol-fed animals exhibited extensive intimal thicken-
ing due to stratified lipid deposits that were sur-
rounded by a collagenous network. The arch region
was noted to display more advanced lesions and
contained what appeared to be deposits of crystalline
cholesterol as well as a few isolated necrotic foci as
 .detected by H and E staining data not shown .
Representative sections of the thoracic aorta of con-
 .trol animals fed standard rabbit chow Panel A , of
 .saline-treated cholesterol-fed animals Panel B or
 .LUV-treated cholesterol-fed animals Panel C are
illustrated in Fig. 8. Note that lesions present in
 .LUV-treated animals Panel C manifest less lipid
deposits and show moderately reduced plaque thick-
ening when compared to saline-treated cholesterol-fed
 .animals Panel B . This is also shown in Table 1
which summarizes the intimal-to-medial ratios ob-
tained after measuring intimal and medial widths
from photographs of sections derived from the arch,
thoracic or abdominal areas. The arch and thoracic
regions of LUV-treated animals, showed small reduc-
tions in intimal-to-ratios, however, no changes were
detected in the abdominal aorta. It is important to
Fig. 8. Representative sections obtained from the thoracic aorta.
Animals fed the standard diet only, regardless of whether they
were treated with vesicles or saline, do not exhibit any sign of
 .plaque formation Panel A . In contrast, saline-treated choles-
terol-fed animals had extensive intimal thickening and lesions
were rich in lipid deposits that were surrounded by collagenous
 .tissue Panel B . Animals that received LUV treatments show
reduced severity of the lesions with what appears to be less lipid
 .and a reduction in plaque thickening Panel C . Sections were
stained with Weigart’s-van Gieson’s, magnification 10=.
note that these measurements are only approximates
of intimal and medial widths since the tissues were
not isolated under perfusion techniques. Nevertheless,
using a limited number of animals, these results may
suggest that the depletion of cholesterol from lesions
by LUVs may reduce lesion bulk. No apparent differ-
ences were detected in the morphology of aortas
between LUV-treated and saline-treated animals that
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Table 1
Measurement of intimal-to-medial ratios in the different regions
of the aorta of LUV-treated and saline-treated cholesterol-fed
animalsa
Portion SignificanceIntimal-to-medial ratios
 .of aorta P valueLUV-treated Saline-treated
Arch 1.51"0.55 1.76"0.94 N.S.
Thoracic 1.34"0.73 1.93"1.12 P -0.05
Abdominal 1.84"0.95 1.81"1.25 N.S.
a Data collected from aortic segments obtained from ns3 ani-
mals.
were maintained on the standard diet throughout the
study.
3.8. Li˝er cholesterol content
Cholesterol feeding of rabbits often leads to the
accumulation of cholesterol in a number of tissues
including the liver. However, upon returning animals
to regular rabbit chow, tissue cholesterol levels usu-
ally revert to normal within a month, with the excep-
w xtion of those found in arterial lesions 28 . We found
that the cholesterol levels of LUV-treated cholesterol-
fed animals were 8"3 mmolrg wet liver weight and
were comparable to control animals maintained on
standard chow having levels of 8"1 mmolrg wet
weight, whereas saline-treated cholesterol-fed ani-
mals exhibited levels of 11"4 mmolrg wet weight.
Although these differences were not statistically sig-
nificant, they results are consistent with those found
w xby Adams et al. 29 who note that the infusion of
polyunsaturated phospholipids alleviate fatty livers in
the cholesterol-fed rabbit.
4. Discussion
Repeated injections of EPC LUVs, reduced the
aortic cholesterol content, the degree of surface plaque
involvement and lesion thickness in cholesterol-fed
rabbits. Moreover, because lipid content and surface
plaque involvement were not significantly different
between saline-treated animals and animals sacrificed
prior to treatment, it is most likely that LUV-treat-
ment resulted in regression of atherosclerosis and not
simply reduced progression. Our data is in general
agreement with earlier work demonstrating that phos-
pholipid infusions can promote the reversal of
w xatheroma 15,17,21 . However, unlike previous stud-
ies, the data reported here was generated with a well
characterized vesicle formulation, and prepared using
materials and techniques validated for clinical use in
the field of liposomal drug delivery.
The LUV formulation used in this rabbit study was
administered as a bolus injection without visible dis-
comfort to the animals. The circulating half-life was
 .approximately 30 h see Fig. 3 , consequently, treat-
ing bi-weekly would have been possible. Under those
circumstances, treatment might have resulted in even
more removal of lipid from atherosclerotic lesions.
The data indicated that the most extensive lipid re-
moval occurred in the thoracic region of the aorta,
which were observed to be lipid-rich, softer, and
more malleable to the touch than lesions in the arch.
In this regard, it is interesting to note that )80% of
fatal heart attacks are associated with the rupture of
unstable plaque, where a lipid mixture composed of
extracellular deposits of UC and CE is extruded into
the vessel lumen through tears in the fibrous cap
w xcovering the lesion 30 . Lipid extruded in this way
likely blocks critical coronary arterioles and the dam-
aged lesions promote the formation of blood clots,
which can further compound the occlusion. Only soft,
lipid-rich plaque laden with foam cell macrophages,
appear to be rupture-prone. It is this type of lesion
that appears to be most responsive to LUV-induced
lipid removal. Considering that the accumulation of
UC and CE in lesions is a gradual process that occurs
over many years, it is especially notable that lipo-
some infusions can dramatically change cholesterol
dynamics and may reverse years of cholesterol accu-
mulation during weeks of therapy. The mobilization
of cholesterol from arterial wall cells may also have
other beneficial effects. It is known that vessel wall
cells enriched with cholesterol or oxidized derivatives
w xshow substantial disfunction 31–34 . For example,
cholesterol-enriched endothelial cells do not produce
w xendothelial-derived relaxing factor 35,36 , and
cholesterol-enriched smooth muscle cells exhibit en-
w xhanced proliferation 37 . These effects can be re-
versed in vitro by HDL-mediated removal of excess
w xcellular UC 38 . It is tempting to speculate that
treatment with LUVs should accomplish the same in
vivo quickly and directly.
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The mechanisms that surround LUV-induced
cholesterol mobilization are not fully understood.
However, it is likely that in vivo, there is a co-oper-
ation between LUVs and plasma lipoproteins. More-
over, the relative contributions of remodeling and
shuttling in vivo are not known. Mechanistic work in
vitro shows that LUVs alone were very inefficient at
causing the mobilization of cellular cholesterol, al-
though cells were fully exposed in monolayer culture
w x11,39 . This is likely compounded in vivo, because
LUVs are too large to penetrate the vasculature and
thus cannot enter the interstitium to access cellular
cholesterol or extracellular deposits buried deep
w xwithin lesions owing to the rupture of cells 40 . In
contrast, HDL are capable of promoting the efficient
mobilization of cholesterol from cells grown in cul-
w x .ture 39 and references therein and are able to
w xaccess lesions and localize throughout plaques 41 .
w xMoreover, Badimon et al. 42 have recently claimed
that the intravenous injection of HDL induces a
regression of atherosclerosis in the cholesterol-fed
rabbit. Several lines of evidence that suggest that
remodeling and shuttling are important events for
LUV-induced cholesterol mobilization in vivo are as
follows. First, it is generally accepted that HDL
rapidly gives up its cholesterol to acceptor mem-
w xbranes 10,43 and interestingly, following LUV
treatment there is a transient drop in lipoprotein C:P
 w x.ratios see Fig. 6 and 10 . Although we do not have
direct evidence, it is reasonable to predict that be-
cause LUVs present an enormous surface area of
 .initially cholesterol free bilayer they can sequester
HDL UC, consistent with the idea that remodeling
occurs. The prediction is that this remodeled lipopro-
tein can then scavenge more sterol from accessible
tissue sites. Second, our data suggest that after the
initial decrease in lipoprotein C:P ratio, these gradu-
ally return to normal, and mirror the rate at which
LUVs accumulate cholesterol. Because UC entering
the blood pool does not appear to be derived from
w xcirculating erythrocytes 10 , and a net depletion of
peripheral tissue cholesterol stores have been re-
w xported 44 , it is likely that plasma lipoproteins are
capable of extracting cholesterol from peripheral
sources, consistent with idea of shuttling. The
lipoprotein species responsible for this co-operation
is not known. Recent evidence suggests that discoidal
HDL particles exhibiting preb mobility on an agarose
gel are very efficient at promoting the removal of
w xcholesterol from cell surfaces 45,46 . Although our
w xin vitro studies 11 have demonstrated that the co-in-
cubation of HDL and LUVs at LUV-to-HDL phos-
.pholipid ratios of 10:1 results in the preservation of
the integrity of both particles with no apparent gener-
ation of preb-migrating species, the relative contribu-
tion of preb-migrating acceptors in vivo remains to
be determined.
It is well documented that LUVs are cleared mainly
by the fixed macrophages of the liver and spleen, and
to a lesser extent also by hepatocytes through endocy-
w xtosis 47,48 . In fact, using radioisotopic tracers to
track liposomal deposition, approximately 80% of the
w xliposomal dose is cleared by the liver 10,19 . More-
over, at doses typically used in liposomal drug deliv-
ery, others have demonstrated that liposomal lipid
can be converted into bile acids by the liver and then
w xexcreted 48,49 . However, the ways by which the
liver disposes of excess peripheral tissue cholesterol
delivered by LUVs remains to be determined. Studies
aimed at examining the interactions between Kupffer
and parenchymal cells may provide useful insights
into a unique catabolic pathway especially since
LUV-delivered cholesterol appears to be directed to a
distinct regulatory pool in the liver that does not
provoke a subsequent rise in plasma LDL concentra-
w xtions 14 .
A major goal for the treatment of atherosclerotic
disease is to stabilize rupture-prone areas. Future
management and possible reversal of atherosclerotic
disease, probably lies in pursuing therapies which
enhance the removal of arterial wall lipid to stabilize
w xlesions whilst suppressing LDL levels 6 . Numerous
experimental and clinical studies document the bene-
w xfits of aggressive lipid-lowering therapies 50 or
antioxidant treatments to decrease LDL concentra-
w xtions and prevent oxidized LDL formation 2 , which
in turn, presumably can remodel plaque content.
Moreover, there is also strong epidemiological evi-
dence that low levels of HDL are associated with
increased atherosclerotic risk while drug therapies
and lifestyle changes which increase HDL concentra-
tion reduce the risk of developing atherosclerosis
w x51 . The amounts of HDL required in vitro for the
synergistic removal of cellular cholesterol with HDL
w xare remarkably low 11 . For this reason, it is antici-
pated that LUV therapy should be capable of mobiliz-
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ing tissue cholesterol even in low-HDL states and
could represent a more general form of therapy for
the large number of patients at risk of developing
w xatherosclerosis due to low levels of HDL 52 . Al-
though the phospholipid dose of 300 mgrkg em-
ployed in this study is considerably higher than is
presently used in liposomal drug delivery formula-
tions, these lipid levels are well below the amounts of
total lipid given to patients receiving daily parenteral
nutrition in the form of Intralipid, for example. More-
over, the bolus injection of EPC LUVs given to
rabbits in this study were very well tolerated, and it is
anticipated that LUVs could be administered in the
clinic to humans using similar rapid infusion times,
thus avoiding the need for hospitalization. The results
presented here are comparable to those reported fol-
w xlowing LDL apheresis 53 . This involves the ex vivo
removal of LDL from plasma when blood from a
patient is passed through an affinity column that
selectively binds apoB-rich lipoproteins. The removal
of LDL from the circulation radically reduces plasma
cholesterol levels and apparently promotes the re-
moval of cholesterol from peripheral tissues. Al-
though LDL apheresis can promote significant re-
gression, the procedure is highly invasive and re-
quires long and costly dialysis times.
Finally, phospholipid therapy does not compete
with existing drugs currently used to lower plasma
w xcholesterol levels 1,54 . For example, bile acid bind-
ing resins promote the excretion of bile salts, which
in turn directs more cholesterol to bile synthesis and
stimulates expression of LDL receptors. Another class
of drugs common in this area are the statins, which
inhibit HMG-CoA reductase, the rate limiting en-
zyme in cholesterol biosynthesis. Recent clinical tri-
als have demonstrated that in combination, these two
types of drugs act additively to reduce plasma choles-
 w x.terol levels in many patients reviewed in 6 . How-
ever, this is still often insufficient to bring levels
within a low risk, normal range which can be ex-
pected to prevent progression of disease. The ability
of LUVs to bring about a reduction in the cholesterol
content of atheroma inspite of persisting elevated
plasma cholesterol levels, suggests that LUVs could
provide therapeutic benefits to hypercholesterolemic
individuals via a mechanism that is additive and not
competitive with currently available therapy.
In summary, the repeated injections of LUVs pro-
mote a significant reduction in the lipid content of
atheroma in the cholesterol-fed rabbit. This lipid
mobilization was observed inspite of persisting ele-
vated plasma cholesterol concentrations in animals
during the treatment period. These results suggests
that phospholipid therapy using LUVs may be a
useful for the treatment of atherosclerosis in humans.
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